PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerview.com
Joyce O’Shaughnessy, MD - Evidence Informing Practice: Changing Standards of Care for Use of CDK4 and 6 Inhibitors in the Treatment of Breast Cancer
Go online to PeerView.com/BKK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, breast cancer experts discuss the latest evidence on the use of CDK4 and 6 inhibitors in the management of patients with HR-positive, HER2-negative breast cancer. An essential overview of mechanisms of action of this therapeutic class, similarities/differences among the agents, and latest approvals/indications is provided, along with a summary and analysis of the current state of the science. Practicalities of clinical integration of the CDK4 and 6 inhibitors are also explored, with a focus on navigating the current treatment landscape and making individualized clinical decisions. Upon completion of this activity, participants should be better able to: Describe the rationale for use, mechanism of action, and characteristics (including similarities/differences) of the CDK4 and 6 inhibitors in breast cancer, Analyze the latest efficacy (including OS), safety, and other key data from clinical trials assessing CDK4 and 6 inhibitors in breast cancer, and relevant implications for clinical practice, Discuss the relevant patient-, disease-, and treatment-related factors as well as promising prognostic/predictive biomarkers that could be used to guide selection of patients who would benefit from CDK4 and 6 inhibitors, Incorporate CDK4 and 6 inhibitors alone or in combination into treatment plans for appropriate patients with hormone receptor–positive, HER2-negative advanced breast cancer according to relevant evidence, clinical guidelines, predictive factors, and patient needs and preferences, Manage treatment-related toxicities in patients with breast cancer undergoing treatment with CDK4 and 6 inhibitors to maintain optimal adherence and promote favorable outcomes.